Videla L., Benejam B., Carmona-Iragui M., Barroeta I., Fernández S., Arranz J., Azzahchi S.E., Altuna M., Padilla C., Valldeneu S., Pegueroles J., Montal V., Aranha M.R., Vaqué-Alcázar L., Iulita M.F., Alcolea D., Bejanin A., Videla S., Blesa R., Lleó A., Fortea J.. Cross-sectional versus longitudinal cognitive assessments for the diagnosis of symptomatic Alzheimer's disease in adults with Down syndrome. ALZHEIMERS & DEMENTIA. 2023; 19(9)DOI:10.1002/alz.13073. PMID:37038748. IF:13.100(Q1/1D).

Aranha, MR, Iulita M.F., Montal V., Pegueroles J., Bejanin A., Vaqué-Alcázar L., Grothe M.J., Carmona-Iragui M., Videla L., Benejam B., Arranz J., Padilla C., Valldeneu S., Barroeta I., Altuna M., Fernández S., Ribas L., Valle-Tamayo N., Alcolea D., González-Ortiz S., Bargalló N., Zetterberg H., Blennow K., Blesa R., Wisniewski T., Busciglio J., Cuello A.C., Lleó A., Fortea J.. Basal forebrain atrophy along the Alzheimer's disease continuum in adults with Down syndrome. ALZHEIMERS & DEMENTIA. 2023; 19(11)DOI:10.1002/alz.12999. PMID:37021589. IF:13.100(Q1/1D).

Barroeta, I, Videla, L, Carmona-Iragui, M, Fortea, J, Rafii, MS. Current advances and unmet needs in Alzheimer's disease trials for individuals with Down syndrome: Navigating new therapeutic frontiers. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70258. PMID:40528298. IF:11.100(Q1/1D).

Sauer, M, Gomes, BF, Shahrouki, P, Lantero-Rodriguez, J, Montoliu-Gaya, L, Camporesi, E, Belbin, O, Alcolea, D, Kumar, A, Sharma, M, Singh, S, Brinkmalm, G, Gobom, J, Carmona-Iragui, M, Schöll, M, Janelidze, S, Deep, G, Blennow, K, Zetterberg, H, Brinkmalm, A, Lleó, A, Fortea, J, Hansson, O, Ashton, NJ, Nilsson, J. Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome. ALZHEIMERS & DEMENTIA. 2025; 21(6)DOI:10.1002/alz.70241. PMID:40522075. IF:11.100(Q1/1D).